<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761891</url>
  </required_header>
  <id_info>
    <org_study_id>061190</org_study_id>
    <nct_id>NCT00761891</nct_id>
  </id_info>
  <brief_title>Validation of an Assay to Measure Cyclooxygenase-1 Activity</brief_title>
  <official_title>Validation of an Ex Vivo Cyclooxygenase-1 Catalytic Assay in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain a reference range for a newly developed assay of ex
      vivo platelet COX-1 activity in normal volunteers taking a routine clinical dose of aspirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aspirin has been shown to reduce cardiovascular events in at-risk individuals, but some
      aspirin-treated patients fail to exhibit expected changes in bleeding time and platelet
      aggregation. Recent evidence has correlated aspirin &quot;non-response&quot; to poor cardiovascular
      outcomes.

      In order to study the mechanisms of aspirin resistance, an assay is needed to measure the
      catalytic activity of platelet cyclooxygenase (which should be inhibited by aspirin). A
      common assay in general use is the measurement of thromboxane B2 production in clotting whole
      blood. This measure, however, is influenced by genetic and environmental variations in the
      glass-activated coagulation pathway, albumin binding capacity, platelet activation pathways,
      arachidonic acid pools, and phospholipase activity.

      Our laboratory has developed a direct assay of platelet cyclooxygenase (COX-1) activity that
      is not influenced by these variations. This study will generate a reference range in normal
      volunteers taking a routine clinical dose of aspirin (81mg daily) for this assay. In
      addition, by using two aspirin formulations (enteric-coated and chewable), the study design
      additionally allows the secondary comparison of the effects of these two formulations on
      COX-1 inhibition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>d8-thromboxane B2 generated in ex vivo platelet COX-1 catalytic assay</measure>
    <time_frame>Baseline and after 2 weeks of aspirin</time_frame>
    <description>measure d8-thromboxane B2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation by optical aggregometry</measure>
    <time_frame>Baseline and after 2 weeks of aspirin</time_frame>
    <description>Measure platelet aggregation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum thromboxane B2</measure>
    <time_frame>Baseline and after 2 weeks of aspirin</time_frame>
    <description>Measure serum thromboxane B2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary 11-dehydro-thromboxane B2</measure>
    <time_frame>Baseline and after 2 weeks of aspirin</time_frame>
    <description>Measure Urinary 11-dehydro-thromboxane B2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary prostacyclin metabolite</measure>
    <time_frame>Baseline and after 2 weeks of aspirin</time_frame>
    <description>Measure Urinary prostacyclin metabolite</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Enteric-coated aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>81 mg daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chewable aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>81 mg daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-coated aspirin</intervention_name>
    <description>enteric-coated aspirin 81mg daily for 2 weeks</description>
    <arm_group_label>Enteric-coated aspirin</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chewable aspirin</intervention_name>
    <description>chewable aspirin 81mg daily for 2 weeks</description>
    <arm_group_label>Chewable aspirin</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoker

          -  No chronic medical illness

          -  No chronic medications

        Exclusion Criteria:

          -  Aspirin/NSAID use in preceding 14 days

          -  History of chronic NSAID use

          -  Currently taking NSAIDs, opioid analgesics, corticosteroids, or anticoagulants

          -  History of coronary artery disease, myocardial infarction, coronary artery bypass
             grafting, percutaneous angioplasty, diabetes mellitus, or stroke.

          -  History of hypertension

          -  Body mass index &gt; 35

          -  History of gastric, duodenal, or esophageal ulcers or serious gastrointestinal bleed

          -  History of frequent headaches, pain syndrome, or other condition requiring frequent
             use of analgesics

          -  History of adverse reactions to aspirin

          -  Screening platelet count &lt; 100,000/ul or &gt; 500,000/ul

          -  Screening hematocrit &lt; 35% or &gt; 50%

          -  Weight less than 110 pounds

          -  Pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Oates, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>John Oates</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>cyclooxygenase-1</keyword>
  <keyword>aspirin resistance</keyword>
  <keyword>aspirin nonresponse</keyword>
  <keyword>platelet</keyword>
  <keyword>Normal volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 10, 2017</submitted>
    <returned>June 26, 2017</returned>
    <submitted>March 19, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

